{"id":24300,"date":"2024-05-13T16:11:52","date_gmt":"2024-05-13T14:11:52","guid":{"rendered":"https:\/\/ggba.swiss\/?p=24300"},"modified":"2024-05-13T16:11:53","modified_gmt":"2024-05-13T14:11:53","slug":"ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease\/","title":{"rendered":"AC Immune and Takeda sign USD 100 million deal to treat Alzheimer\u2019s disease"},"content":{"rendered":"\n<p>Lausanne-based biopharmaceutical company <a href=\"https:\/\/www.acimmune.com\/\">AC Immune<\/a> and Japanese pharmaceutical giant <a href=\"https:\/\/www.takeda.com\/\">Takeda<\/a> have announced an exclusive option and license agreement for the global rights to ACI-24.060, a promising active immunotherapy aimed at combating the progression of Alzheimer\u2019s disease.<\/p>\n\n\n\n<p>AC Immune, headquartered at the <a href=\"https:\/\/www.epfl-innovationpark.ch\/\">EPFL Innovation Park<\/a>, has developed ACI-24.060, an innovative candidate designed to target and neutralize toxic forms of amyloid beta (Abeta) \u2014 proteins believed to be key contributors to the neural plaque formation associated with Alzheimer&#8217;s disease. The ongoing ABATE Phase 1b\/2 clinical trial is evaluating ACI-24.060\u2019s potential in patients with prodromal Alzheimer\u2019s and adults with Down syndrome, focusing on its safety, tolerability, and effectiveness in preventing plaque buildup and fostering plaque clearance in the brain.<\/p>\n\n\n\n<p>In the company\u2019s press release, Dr. Andrea Pfeifer, CEO of AC Immune, highlighted the significance of this collaboration with Takeda, pointing out the potential of ACI-24.060 to redefine Alzheimer&#8217;s treatment. \u201cAs pioneers in active immunotherapy, partnering with Takeda at this pivotal phase in development allows us to leverage their extensive expertise and resources to initiate comprehensive Phase 3 trials,\u201d she stated.<\/p>\n\n\n\n<p>Under the terms of the agreement, AC Immune will receive an upfront payment of USD 100 million from Takeda, with potential for additional milestone payments that could total approximately USD 2.1 billion. Takeda will take on the responsibilities of further clinical development, regulatory activities, and global commercialization post-option exercise.<\/p>\n\n\n\n<p>Sarah Sheikh, Head of Neuroscience Therapeutic Area Unit at Takeda, expressed enthusiasm for the partnership, emphasizing the innovative approach of the treatment and its potential to significantly impact those suffering from Alzheimer&#8217;s disease. \u201cThis agreement combines our deep neuroscience expertise with AC Immune\u2019s groundbreaking immunotherapy technology, enhancing our commitment to address critical needs in Alzheimer\u2019s therapy,\u201d she explained.<\/p>\n\n\n\n<p>This strategic collaboration is not only a testament to AC Immune\u2019s innovative capabilities, demonstrated through its SupraAntigen\u00ae and Morphomer\u00ae technology platforms, but also aligns with Takeda\u2019s mission to champion novel therapeutic approaches in its core business areas.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Takeda will receive an exclusive option to license AC Immune&#8217;s ACI-24.060, a breakthrough therapy to combat the progression of Alzheimer&#8217;s disease, for an upfront payment of USD 100 million and potential milestone payments of USD 2.1 billion.<\/p>\n","protected":false},"author":6,"featured_media":24301,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[902,911,886],"class_list":["post-24300","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-personalized-medicine","tag-pharma","tag-rd"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AC Immune and Takeda sign USD 100 million deal | GGBa<\/title>\n<meta name=\"description\" content=\"Takeda will receive an exclusive option to license AC Immune&#039;s ACI-24.060 for an upfront payment of USD 100 million.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AC Immune and Takeda sign USD 100 million deal | GGBa\" \/>\n<meta property=\"og:description\" content=\"Takeda will receive an exclusive option to license AC Immune&#039;s ACI-24.060 for an upfront payment of USD 100 million.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-13T14:11:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-13T14:11:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Takeda-AC-Immune-Alzheimer-2360x1622-1-1024x704.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"704\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"AC Immune and Takeda sign USD 100 million deal to treat Alzheimer\u2019s disease\",\"datePublished\":\"2024-05-13T14:11:52+00:00\",\"dateModified\":\"2024-05-13T14:11:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease\/\"},\"wordCount\":341,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Takeda-AC-Immune-Alzheimer-2360x1622-1.jpeg\",\"keywords\":[\"Personalized Medicine\",\"Pharma\",\"R&amp;D\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/en\/ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease\/\",\"url\":\"https:\/\/ggba.swiss\/en\/ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease\/\",\"name\":\"AC Immune and Takeda sign USD 100 million deal | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Takeda-AC-Immune-Alzheimer-2360x1622-1.jpeg\",\"datePublished\":\"2024-05-13T14:11:52+00:00\",\"dateModified\":\"2024-05-13T14:11:53+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Takeda will receive an exclusive option to license AC Immune's ACI-24.060 for an upfront payment of USD 100 million.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Takeda-AC-Immune-Alzheimer-2360x1622-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Takeda-AC-Immune-Alzheimer-2360x1622-1.jpeg\",\"width\":2360,\"height\":1622,\"caption\":\"AC Immune and Takeda\u2019s partnership marks a pivotal advancement in the quest to offer new hope to millions affected by Alzheimer\u2019s disease worldwide.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AC Immune and Takeda sign USD 100 million deal to treat Alzheimer\u2019s disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AC Immune and Takeda sign USD 100 million deal | GGBa","description":"Takeda will receive an exclusive option to license AC Immune's ACI-24.060 for an upfront payment of USD 100 million.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease\/","og_locale":"en_US","og_type":"article","og_title":"AC Immune and Takeda sign USD 100 million deal | GGBa","og_description":"Takeda will receive an exclusive option to license AC Immune's ACI-24.060 for an upfront payment of USD 100 million.","og_url":"https:\/\/ggba.swiss\/en\/ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2024-05-13T14:11:52+00:00","article_modified_time":"2024-05-13T14:11:53+00:00","og_image":[{"width":1024,"height":704,"url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Takeda-AC-Immune-Alzheimer-2360x1622-1-1024x704.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"AC Immune and Takeda sign USD 100 million deal to treat Alzheimer\u2019s disease","datePublished":"2024-05-13T14:11:52+00:00","dateModified":"2024-05-13T14:11:53+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease\/"},"wordCount":341,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/en\/ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Takeda-AC-Immune-Alzheimer-2360x1622-1.jpeg","keywords":["Personalized Medicine","Pharma","R&amp;D"],"articleSection":["Life sciences"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/en\/ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease\/","url":"https:\/\/ggba.swiss\/en\/ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease\/","name":"AC Immune and Takeda sign USD 100 million deal | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Takeda-AC-Immune-Alzheimer-2360x1622-1.jpeg","datePublished":"2024-05-13T14:11:52+00:00","dateModified":"2024-05-13T14:11:53+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Takeda will receive an exclusive option to license AC Immune's ACI-24.060 for an upfront payment of USD 100 million.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Takeda-AC-Immune-Alzheimer-2360x1622-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Takeda-AC-Immune-Alzheimer-2360x1622-1.jpeg","width":2360,"height":1622,"caption":"AC Immune and Takeda\u2019s partnership marks a pivotal advancement in the quest to offer new hope to millions affected by Alzheimer\u2019s disease worldwide."},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"AC Immune and Takeda sign USD 100 million deal to treat Alzheimer\u2019s disease"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/24300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=24300"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/24300\/revisions"}],"predecessor-version":[{"id":24304,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/24300\/revisions\/24304"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/24301"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=24300"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=24300"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=24300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}